Blinatumomab therapy for B cell acute lymphoblastic leukemia accompanied by persistent or relapsed low-level MRD prior to hematopoietic stem cell transplantation in Chinese children: a case series

Bulletin of the National Research Centre

Case Report

Tonghui Li¹  Fen Chen¹  Yi Liu¹  Sixi Liu¹  Ying Wang¹  Shilin Liu¹  Guichi Zhou¹  Huirong Mai¹  Lulu Wang¹  Xue Tang¹  Feiqiu Wen¹ 

[1] Department of Pediatric Hematology and Oncology, Shenzhen Children’s Hospital, 518000, Shenzhen, China;

关键词: Acute B lymphoblastic leukemia;    Blinatumomab;    Minimal residual disease;    Hematopoietic stem cell transplantation;    China;   

DOI  :  10.1186/s42269-023-00999-x

 received in 2023-01-06, accepted in 2023-02-13,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundBlinatumomab could be successfully used to reduce minimal residual disease (MRD) prior to hematopoietic stem cell transplantation (HSCT) in pediatric B cell precursor acute lymphoblastic leukemia (BCP-ALL), but sound evidence is lacking in China.Case presentationThis retrospective study assessed the application of blinatumomab in B-ALL accompanied by persistent or relapsed low-level MRD before HSCT from April 2019 to July 2021. Two cases (Cases 1 and 2) initially achieved remission with MRD < 0.01% upon conventional therapy but had MRD relapse with MRD ≥ 0.01% but < 1% during maintenance treatment. Case 3 had no response to routine treatment, with high MRD (9.88% and 1.23% at days 19 and 46, respectively). Nevertheless, all patients had undetectable MRD. Cases 2 and 3 had undetectable fusion gene following blinatumomab therapy. By bone marrow monitoring (bone marrow morphology, bone marrow MRD and fusion gene) post-HSCT, the patients were persistently negative until May 15, 2022. No patient had serious adverse events before or during blinatumomab treatment.ConclusionsBlinatumomab therapy showed a good performance for three pediatric cases with detectable but low MRD before HSCT in China. However, further prospective studies with large sample sizes are still needed for further clarification.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 2

12938_2023_1070_Article_IEq19.gif